An Observational Post-Authorization Modified Prescription-Event Monitoring Safety Study to Monitor the Safety and Utilization of Asenapine (Sycrest) in the Primary Care Setting in England
Phase of Trial: Phase IV
Latest Information Update: 07 Aug 2018
Price : $35 *
At a glance
- Drugs Asenapine (Primary)
- Indications Bipolar I disorders; Psychotic disorders
- Focus Adverse reactions
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.
- 26 Jan 2018 Planned End Date changed from 1 May 2017 to 1 Mar 2018.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.